Mega Lifesciences PCL
SET:MEGA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
33.5
44
|
Price Target |
|
We'll email you a reminder when the closing price reaches THB.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Relative Value
The Relative Value of one MEGA stock under the Base Case scenario is 49.17 THB. Compared to the current market price of 34 THB, Mega Lifesciences PCL is Undervalued by 31%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
MEGA Competitors Multiples
Mega Lifesciences PCL Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
TH |
M
|
Mega Lifesciences PCL
SET:MEGA
|
29.6B THB | 1.9 | 16.1 | 7.6 | 8.2 | |
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
749.7B USD | 18.3 | 89.6 | 48.1 | 53.7 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.4T DKK | 12.4 | 35.4 | 24.6 | 28.1 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
372B USD | 4.2 | 25.3 | 12.2 | 15.9 | ||
US |
Merck & Co Inc
NYSE:MRK
|
257.3B USD | 4.1 | 21.2 | 10.7 | 12.8 | ||
CH |
Roche Holding AG
SIX:ROG
|
200.4B CHF | 3.4 | 17.4 | 9.8 | 11.7 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
162.7B GBP | 4.2 | 31.8 | 169.5 | 254 | ||
CH |
Novartis AG
SIX:NOVN
|
179.9B CHF | 4.1 | 11.5 | 10 | 13.9 | ||
IE |
E
|
Endo International PLC
LSE:0Y5F
|
146B USD | 63 | -49.9 | 234.4 | 587.7 |